Li Jiang1,2, Julie Gilbert3, Hugh Langley4, Rahim Moineddin5, Patti A Groome1,2. 1. Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada. 2. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 3. Cancer Care Ontario, Toronto, Ontario, Canada. 4. South East Regional Cancer Program, Kingston General Hospital, Kingston, Ontario, Canada. 5. Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
INTRODUCTION: Breast cancer is detected through screening or through signs and symptoms. In Canada, mammograms for breast cancer screening are offered in organized programs or independently (opportunistic screening). Province of Ontario breast Diagnostic Assessment Units (DAUs) are facility-based programs that provide coordinated breast cancer diagnostic services, as opposed to usual care, in which the primary care provider arranges the tests and consultations. This study describes breast cancer detection method, diagnostic interval and DAU use across Ontario. METHODS: The study cohort consisted of 6898 women with invasive breast cancer diagnosed in 2011. We used the Ontario Cancer Registry linked to administrative health care databases. We determined the detection method using the Ontario Breast Screening Program (OBSP) data and physician claims. The diagnostic interval was the time between the initial screen, specialist referral or first diagnostic test and the cancer diagnosis. The diagnostic route (whether through DAU or usual care) was determined based on the OBSP records and biopsy or surgery location. We mapped the diagnostic interval and DAU coverage geographically by women's residence. RESULTS: In 2011, 36% of Ontario breast cancer patients were screen-detected, with a 48% rate among those aged 50 to 69. The provincial median diagnostic interval was 32 days, with county medians ranging from 15 to 65 days. Provincially, 48.4% were diagnosed at a DAU, and this ranged from zero to 100% across counties. CONCLUSION: The screening detection rate in age-eligible breast cancer patients was lower than published population-wide screening rates. Geographic mapping of the diagnostic interval and DAU use reveals regional variations in cancer diagnostic care that need to be addressed.
INTRODUCTION:Breast cancer is detected through screening or through signs and symptoms. In Canada, mammograms for breast cancer screening are offered in organized programs or independently (opportunistic screening). Province of Ontario breast Diagnostic Assessment Units (DAUs) are facility-based programs that provide coordinated breast cancer diagnostic services, as opposed to usual care, in which the primary care provider arranges the tests and consultations. This study describes breast cancer detection method, diagnostic interval and DAU use across Ontario. METHODS: The study cohort consisted of 6898 women with invasive breast cancer diagnosed in 2011. We used the Ontario Cancer Registry linked to administrative health care databases. We determined the detection method using the Ontario Breast Screening Program (OBSP) data and physician claims. The diagnostic interval was the time between the initial screen, specialist referral or first diagnostic test and the cancer diagnosis. The diagnostic route (whether through DAU or usual care) was determined based on the OBSP records and biopsy or surgery location. We mapped the diagnostic interval and DAU coverage geographically by women's residence. RESULTS: In 2011, 36% of Ontario breast cancerpatients were screen-detected, with a 48% rate among those aged 50 to 69. The provincial median diagnostic interval was 32 days, with county medians ranging from 15 to 65 days. Provincially, 48.4% were diagnosed at a DAU, and this ranged from zero to 100% across counties. CONCLUSION: The screening detection rate in age-eligible breast cancerpatients was lower than published population-wide screening rates. Geographic mapping of the diagnostic interval and DAU use reveals regional variations in cancer diagnostic care that need to be addressed.
Entities:
Keywords:
breast neoplasms/diagnosis; cross-sectional studies; diagnostic services; early detection ofzzm321990cancer; early diagnosis; female; health services research
Authors: Marcello Tonelli; Sarah Connor Gorber; Michel Joffres; James Dickinson; Harminder Singh; Gabriela Lewin; Richard Birtwhistle; Donna Fitzpatrick-Lewis; Nicole Hodgson; Donna Ciliska; Mary Gauld; Yan Yun Liu Journal: CMAJ Date: 2011-11-22 Impact factor: 8.262
Authors: Li Jiang; Julie Gilbert; Hugh Langley; Rahim Moineddin; Patti A Groome Journal: Eur J Cancer Care (Engl) Date: 2018-06-05 Impact factor: 2.520
Authors: Deirdre A Hill; Andrea Nibbe; Melanie E Royce; Anne Marie Wallace; Huining Kang; Charles L Wiggins; Robert D Rosenberg Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-14 Impact factor: 4.254
Authors: Victoria A Kirsh; Anna M Chiarelli; Sarah A Edwards; Frances P O'Malley; Rene S Shumak; Martin J Yaffe; Norman F Boyd Journal: J Natl Cancer Inst Date: 2011-05-03 Impact factor: 13.506
Authors: Marilyn J Borugian; Lisa Kan; Christina C Y Chu; Kathy Ceballos; Karen A Gelmon; Paula B Gordon; Barbara Poole; Scott Tyldesley; Ivo A Olivotto Journal: Can J Public Health Date: 2008 Jul-Aug
Authors: Colleen Webber; Marlo Whitehead; Andrea Eisen; Claire M B Holloway; Patti A Groome Journal: Breast Cancer Res Treat Date: 2021-01-24 Impact factor: 4.872
Authors: Patti A Groome; Colleen Webber; Marlo Whitehead; Rahim Moineddin; Eva Grunfeld; Andrea Eisen; Julie Gilbert; Claire Holloway; Jonathan C Irish; Hugh Langley Journal: JCO Clin Cancer Inform Date: 2019-05
Authors: Steven Habbous; Esha Homenauth; Andriana Barisic; Sharmilaa Kandasamy; Vicky Majpruz; Katharina Forster; Marta Yurcan; Anna M Chiarelli; Patti Groome; Claire M B Holloway; Andrea Eisen Journal: CMAJ Open Date: 2022-04-05
Authors: K Decker; R Moineddin; C Kendell; R Urquhart; N Biswanger; P Groome; M L McBride; M Winget; M Whitehead; E Grunfeld Journal: BMC Fam Pract Date: 2019-11-21 Impact factor: 2.497